50
Participants
Start Date
December 30, 2021
Primary Completion Date
June 26, 2025
Study Completion Date
June 30, 2026
sapablursen
Sapablursen will be administered by SC injection.
Calvary Mater Newcastle Hospital, Waratah
Border Medical Oncology Research Unit, Albury
The Perth Blood Institute, West Perth
O'Neal Comprehensive Cancer Center University of Alabama at Birmingham, Birmingham
Cleveland Clinic Foundation, Cleveland
University of Texas MD Anderson Cancer Center, Houston
Mayo Clinic Hospital, Phoenix
Norris Comprehensive Cancer Center, Los Angeles
University of California Irvine, Orange
John Theurer Cancer Center, Hackensack
McGill University Health Centre, Montreal
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Klinika Hematoonkologii i Transplantacji Szpiku, Lublin
Wojewódzki Szpital Specjalistyczny Sp. z o.o., Słupsk
MICS Centrum Medyczne Toruń, Torun
United Lincolnshire Hospitals NHS Trust, Lincoln
Oxford University Hospitals NHS Foundation Trust, Oxford
University College London Hospitals NHS Foundation Trust, London
Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich
Lead Sponsor
Ionis Pharmaceuticals, Inc.
INDUSTRY